G02, Al Tala-Block D, The Square Al Mamzar, Dubai, UAE P.O. Box 213944 RU
RU
Home News FDA Clears Trial for New MS Drug Lucid-MS

FDA Approves Key Trial for New MS Drug Targeting Nerve Repair

Sep 11, 2026
54 min
11
Sep 11, 2026 15:31
New MS drug could repair nerve damage – FDA clears key trial

## New Approach in MS Treatment

A new drug, Lucid-MS, developed by Quantum Biopharma Ltd., has received approval from the FDA to begin phase two trials in the United States. Unlike existing treatments that focus on suppressing the immune system, Lucid-MS aims to repair and protect the myelin sheath damaged by multiple sclerosis (MS).

## Expert Insights

Dr. Taleb Rooeintan from Sheikh Saqr Al Qasimi Hospital describes this development as a significant shift in MS research. He emphasizes that while the drug represents a promising approach, it is not yet proven to reverse existing disabilities caused by MS. The potential for nerve function recovery depends on various factors, including the extent and duration of neurological damage.

## MS Research in the UAE

Yasmine Mitwally from the National Multiple Sclerosis Society highlights the rapid growth of MS research in the UAE. The country is considered a moderate-high risk zone for MS, with women being disproportionately affected. The UAE's research funding for MS reached 11 million AED in 2025, reflecting a strong commitment to advancing understanding and treatment of the disease.

Read the full story at the source

What you need to know to get Emirates ID?

Leave your details and get a guide as a gift to avoid mistakes

Guide illustration
Article contents